抗体受託製造の世界市場レポート 2025年

抗体受託製造の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR15.4％で298億6,000万米ドルに成長します。予測期間の成長は、研究開発費の増加、二重特異性および多重特異性抗体の拡大、抗体薬物複合体（adcs）の台頭、ヘルスケアインフラの増加、政府のイニシアチブの高まりなどに起因すると考えられます。予測期間における主な動向には、デジタル化とデータ分析、高度な上流技術、新しい下流処理技術、持続可能性への取り組み、開発・製造受託（CDMO）などがあります。

臨床試験件数の増加が予想され、今後数年間の抗体受託製造市場の成長を牽引するとみられます。臨床試験とは、新しい治療や介入、診断方法の安全性や有効性を評価するためにヒトを対象として実施される調査であり、抗体ベースの治療薬や診断薬の利用が増加しています。この急増は、臨床試験のためのタイムリーでコンプライアンスに適合した供給を確保するための高品質抗体への需要を際立たせています。ClinicalTrials.govの2023年5月のデータによると、世界的に登録された臨床試験数は2022年の399,499から2023年には437,533に増加し、これらの試験の約53％が米国外で登録されました。したがって、臨床試験数の増加が抗体受託製造市場拡大の主要な促進要因となっています。

予想される慢性疾患の増加は、抗体受託製造市場を前進させる。慢性疾患は、持続的かつしばしば進行性であることが特徴で、治療には抗体治療が必要です。抗体受託製造は、慢性疾患に関連する特定のタンパク質や細胞を標的として設計された治療用抗体の生産において重要な役割を果たしており、標的を絞った個別化治療を提供しています。米国では、2050年までに50歳以上の人口が61.11%増加すると予測されており、この人口層における慢性疾患の有病率は、2020年の7,152万2,000人から2050年には推定1億4,266万人とほぼ倍増するため、抗体受託製造の需要は大幅に増加すると予想されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界抗体受託製造PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の抗体受託製造市場：成長率分析
• 世界の抗体受託製造市場の実績：規模と成長, 2019-2024
• 世界の抗体受託製造市場の予測：規模と成長, 2024-2029, 2034F
• 世界抗体受託製造総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗体受託製造市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• ポリクローナル抗体
• その他の製品
• 世界の抗体受託製造市場：ソース別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 哺乳類
• 微生物
• 世界の抗体受託製造市場事業規模別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前臨床
• 臨床
• 商業用
• 世界の抗体受託製造市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイオ医薬品企業
• 調査室
• その他のエンドユーザー
• 世界の抗体受託製造市場、モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 治療用モノクローナル抗体
• 診断用モノクローナル抗体
• 世界の抗体受託製造市場、ポリクローナル抗体のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 調査ポリクローナル抗体
• 治療用ポリクローナル抗体
• 世界の抗体受託製造市場、その他の製品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 二重特異性抗体
• 抗体薬物複合体（ADC）
• 融合タンパク質

第7章 地域別・国別分析

• 世界の抗体受託製造市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の抗体受託製造市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗体受託製造市場：競合情勢
• 抗体受託製造市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim Biopharmaceuticals GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Lonza Group AG
• Labcorp Drug Development
• Catalent Inc.
• Charles River Laboratories International Inc.
• Merck KGaA
• Samsung Biologics Co. Ltd.
• Wuxi Biologics Cayman Inc
• Siegfried Holding AG
• Recipharm AB
• Emergent BioSolutions Inc.
• Aenova Group
• Cambrex Corporation
• Aldevron LLC
• Novasep Holding SAS
• Synthon

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗体受託製造市場2029：新たな機会を提供する国
• 抗体受託製造市場2029：新たな機会を提供するセグメント
• 抗体受託製造市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Antibody contract manufacturing involves the outsourcing of antibody production and manufacturing to specialized contract manufacturing organizations (CMOs). These organizations possess the necessary expertise, infrastructure, and resources required for the manufacturing of antibodies on behalf of pharmaceutical and biotechnology companies.

The primary products of antibody contract manufacturing include monoclonal antibodies, polyclonal antibodies, and other antibody-related products. Monoclonal antibodies (mAbs) are specifically designed to target a particular antigen, and antibody contract manufacturing plays a crucial role in producing monoclonal antibodies on a large scale. This ensures consistent quality and quantity, meeting the demands for therapeutic or diagnostic applications. These antibodies are derived from sources such as mammals and microbes, and the manufacturing processes span preclinical, clinical, and commercial scales of operation. The end users of these antibody products include biopharmaceutical companies, research laboratories, and other entities.

The antibody contract manufacturing research report is one of a series of new reports from The Business Research Company that provides antibody contract manufacturing market statistics, including the antibody contract manufacturing industry's global market size, regional shares, competitors with a antibody contract manufacturing market share, detailed antibody contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the antibody contract manufacturing industry. This antibody contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antibody contract manufacturing market size has grown rapidly in recent years. It will grow from $14.8 billion in 2024 to $16.84 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to increased demand for monoclonal antibodies, shift towards personalized medicine, cost optimization, stringent regulatory requirements, globalization of biologics

The antibody contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $29.86 billion in 2029 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to increasing r&d spending, expansion of bispecific and multispecific antibodies, rise of antibody-drug conjugates (adcs), increasing healthcare infrastructure, growing government initiatives. Major trends in the forecast period include digitalization and data analytics, advanced upstream technologies, novel downstream processing techniques, sustainability initiatives, contract development and manufacturing integration (CDMO).

The anticipated rise in the number of clinical trials is poised to drive the growth of the antibody contract manufacturing market in the coming years. Clinical trials, which involve research studies conducted with human participants to assess the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures, are witnessing an increase in the utilization of antibody-based therapeutics or diagnostics. This surge accentuates the demand for high-quality antibodies to ensure a timely and compliant supply for clinical trials. According to ClinicalTrials.gov's May 2023 data, the number of registered clinical trial studies globally increased from 399,499 in 2022 to 437,533 in 2023, with around 53% of these studies registered outside the United States. Hence, the growing number of clinical trials is a key driver behind the expansion of the antibody contract manufacturing market.

The expected growth in the prevalence of chronic diseases is set to propel the antibody contract manufacturing market forward. Chronic diseases, characterized by their persistent and often progressive nature, require therapeutic antibodies for treatment. Antibody contract manufacturing plays a vital role in producing these therapeutic antibodies designed to target specific proteins or cells associated with chronic conditions, offering targeted and personalized treatment. With the U.S. population aged 50 and above projected to increase by 61.11% by 2050, and the prevalence of chronic diseases in this demographic nearly doubling, from 71.522 million in 2020 to an estimated 142.66 million by 2050, the demand for antibody contract manufacturing is expected to rise significantly.

Major companies in the antibody contract manufacturing market are concentrating on innovations such as single-use technology (SUT), which minimizes cross-contamination risks and reduces operational costs. SUT refers to disposable components and systems utilized in biopharmaceutical manufacturing processes. For instance, in September 2024, Merck & Co., a US-based pharmaceutical company, launched the Mobius ADC Reactor, aimed at enhancing the manufacturing of antibody-drug conjugates. This new single-use reactor significantly improves production efficiency by 70% compared to traditional stainless steel or glass methods. Its single-use design reduces cross-contamination risks and operational costs, enabling faster turnaround times. Additionally, advanced film technology enhances bag strength and leak resistance, ensuring the integrity of highly potent active pharmaceutical ingredients. This innovation supports biopharmaceutical companies in producing essential therapies more safely and efficiently.

Major companies in the antibody contract manufacturing market are focused on developing innovative solutions such as bispecific antibody platforms. These platforms play a pivotal role in the development of bispecific antibodies, utilizing scientific and technological approaches to create specialized antibodies. For instance, in September 2022, Samsung Biologics launched 'S-DUAL' and 'DEVELOPICK.' S-DUAL, a high-yield bispecific antibody platform, boasts a remarkable 99% success rate in chain pairing, optimizing manufacturing ease and achieving elevated titer and purity. DEVELOPICK, a rapid accessibility platform, enables the screening of molecules in early development, identifying candidates with optimal potential for progression to Investigational New Drug (IND) and Biological License Application (BLA). This comprehensive risk assessment platform empowers clients to evaluate drug candidates efficiently.

In April 2022, Asahi Kasei Medical Co., Ltd. acquired Bionova Scientific LLC for an undisclosed amount. This strategic acquisition expanded Asahi Kasei Medical's bioprocess business by incorporating a biopharmaceutical CDMO (contract development and manufacturing organization). Bionova Scientific LLC, a U.S.-based CDMO, specializes in developing and manufacturing recombinant protein products, including antibodies.

Major companies operating in the antibody contract manufacturing market include AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Fujifilm Holdings Corporation, Eurofins Scientific SE, Lonza Group AG, Labcorp Drug Development, Catalent Inc., Charles River Laboratories International Inc., Merck KGaA, Samsung Biologics Co. Ltd., Wuxi Biologics Cayman Inc, Siegfried Holding AG, Recipharm AB, Emergent BioSolutions Inc., Aenova Group, Cambrex Corporation, Aldevron LLC, Novasep Holding SAS, Synthon, KBI Biopharma Inc., Nitto Avecia Pharma Services Inc., Cytovance Biologics Inc., AGC Biologics S.p.A.

North America was the largest region in the antibody contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antibody contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The antibody contract manufacturing market includes revenues earned by entities by providing services such as cell line development, process optimization, and the manufacturing of clinical trial materials. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antibody Contract Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antibody contract manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antibody contract manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antibody contract manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Monoclonal Antibodies; Polyclonal Antibodies; Other Products
• 2) By Source: Mammalian; Microbial
• 3) Scale Of Operation: Preclinical; Clinical; Commercial
• 4) By End-User: Biopharmaceutical Companies; Research Laboratories; Other End Users
• Subsegments:
• 1) By Monoclonal Antibodies: Therapeutic Monoclonal Antibodies; Diagnostic Monoclonal Antibodies
• 2) By Polyclonal Antibodies: Research Polyclonal Antibodies; Therapeutic Polyclonal Antibodies
• 3) By Other Products: Bispecific Antibodies; Antibody-Drug Conjugates (ADCs); Fusion Proteins
• Companies Mentioned: AbbVie Inc.; Thermo Fisher Scientific Inc.; Boehringer Ingelheim Biopharmaceuticals GmbH; Fujifilm Holdings Corporation; Eurofins Scientific SE
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antibody Contract Manufacturing Market Characteristics

3. Antibody Contract Manufacturing Market Trends And Strategies

4. Antibody Contract Manufacturing Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Antibody Contract Manufacturing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antibody Contract Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antibody Contract Manufacturing Market Growth Rate Analysis
• 5.4. Global Antibody Contract Manufacturing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antibody Contract Manufacturing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antibody Contract Manufacturing Total Addressable Market (TAM)

6. Antibody Contract Manufacturing Market Segmentation

• 6.1. Global Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Polyclonal Antibodies
• Other Products
• 6.2. Global Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mammalian
• Microbial
• 6.3. Global Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preclinical
• Clinical
• Commercial
• 6.4. Global Antibody Contract Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopharmaceutical Companies
• Research Laboratories
• Other End Users
• 6.5. Global Antibody Contract Manufacturing Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Therapeutic Monoclonal Antibodies
• Diagnostic Monoclonal Antibodies
• 6.6. Global Antibody Contract Manufacturing Market, Sub-Segmentation Of Polyclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Research Polyclonal Antibodies
• Therapeutic Polyclonal Antibodies
• 6.7. Global Antibody Contract Manufacturing Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bispecific Antibodies
• Antibody-Drug Conjugates (ADCs)
• Fusion Proteins

7. Antibody Contract Manufacturing Market Regional And Country Analysis

• 7.1. Global Antibody Contract Manufacturing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antibody Contract Manufacturing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antibody Contract Manufacturing Market

• 8.1. Asia-Pacific Antibody Contract Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antibody Contract Manufacturing Market

• 9.1. China Antibody Contract Manufacturing Market Overview
• 9.2. China Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antibody Contract Manufacturing Market

• 10.1. India Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antibody Contract Manufacturing Market

• 11.1. Japan Antibody Contract Manufacturing Market Overview
• 11.2. Japan Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antibody Contract Manufacturing Market

• 12.1. Australia Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antibody Contract Manufacturing Market

• 13.1. Indonesia Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antibody Contract Manufacturing Market

• 14.1. South Korea Antibody Contract Manufacturing Market Overview
• 14.2. South Korea Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antibody Contract Manufacturing Market

• 15.1. Western Europe Antibody Contract Manufacturing Market Overview
• 15.2. Western Europe Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antibody Contract Manufacturing Market

• 16.1. UK Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antibody Contract Manufacturing Market

• 17.1. Germany Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antibody Contract Manufacturing Market

• 18.1. France Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antibody Contract Manufacturing Market

• 19.1. Italy Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antibody Contract Manufacturing Market

• 20.1. Spain Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antibody Contract Manufacturing Market

• 21.1. Eastern Europe Antibody Contract Manufacturing Market Overview
• 21.2. Eastern Europe Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antibody Contract Manufacturing Market

• 22.1. Russia Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antibody Contract Manufacturing Market

• 23.1. North America Antibody Contract Manufacturing Market Overview
• 23.2. North America Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antibody Contract Manufacturing Market

• 24.1. USA Antibody Contract Manufacturing Market Overview
• 24.2. USA Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antibody Contract Manufacturing Market

• 25.1. Canada Antibody Contract Manufacturing Market Overview
• 25.2. Canada Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antibody Contract Manufacturing Market

• 26.1. South America Antibody Contract Manufacturing Market Overview
• 26.2. South America Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antibody Contract Manufacturing Market

• 27.1. Brazil Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antibody Contract Manufacturing Market

• 28.1. Middle East Antibody Contract Manufacturing Market Overview
• 28.2. Middle East Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antibody Contract Manufacturing Market

• 29.1. Africa Antibody Contract Manufacturing Market Overview
• 29.2. Africa Antibody Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antibody Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antibody Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antibody Contract Manufacturing Market Competitive Landscape And Company Profiles

• 30.1. Antibody Contract Manufacturing Market Competitive Landscape
• 30.2. Antibody Contract Manufacturing Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Boehringer Ingelheim Biopharmaceuticals GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis

31. Antibody Contract Manufacturing Market Other Major And Innovative Companies

• 31.1. Lonza Group AG
• 31.2. Labcorp Drug Development
• 31.3. Catalent Inc.
• 31.4. Charles River Laboratories International Inc.
• 31.5. Merck KGaA
• 31.6. Samsung Biologics Co. Ltd.
• 31.7. Wuxi Biologics Cayman Inc
• 31.8. Siegfried Holding AG
• 31.9. Recipharm AB
• 31.10. Emergent BioSolutions Inc.
• 31.11. Aenova Group
• 31.12. Cambrex Corporation
• 31.13. Aldevron LLC
• 31.14. Novasep Holding SAS
• 31.15. Synthon

32. Global Antibody Contract Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antibody Contract Manufacturing Market

34. Recent Developments In The Antibody Contract Manufacturing Market

35. Antibody Contract Manufacturing Market High Potential Countries, Segments and Strategies

• 35.1 Antibody Contract Manufacturing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antibody Contract Manufacturing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antibody Contract Manufacturing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer